Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Calcitonin.

P M Sexton1, D M Findlay, T J Martin

  • 1Molecular Pharmacology Unit, Department of Pharmacology, The University of Melbourne, Victoria, Parkville 3052, Australia. p.sexton@pharmacology.unimelb.edu.au

Current Medicinal Chemistry
|October 16, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Elevated levels of active Transforming Growth Factor β1 in the subchondral bone relate spatially to cartilage loss and impaired bone quality in human knee osteoarthritis.

Osteoarthritis and cartilage·2022
Same author

Bone marrow lesions in knee osteoarthritis: regional differences in tibial subchondral bone microstructure and their association with cartilage degeneration.

Osteoarthritis and cartilage·2019
Same author

Differential engagement of polar networks in the glucagon-like peptide 1 receptor by endogenous variants of the glucagon-like peptide 1.

Biochemical pharmacology·2018
Same author

Recombinant sclerostin antagonizes effects of ex vivo mechanical loading in trabecular bone and increases osteocyte lacunar size.

American journal of physiology. Cell physiology·2017
Same author

The class B G-protein-coupled GLP-1 receptor: an important target for the treatment of type-2 diabetes mellitus.

International journal of obesity supplements·2016
Same author

Semaphorin-3a, neuropilin-1 and plexin-A1 in prosthetic-particle induced bone loss.

Acta biomaterialia·2015
Same journal

Screening of Medicinal and Edible Homology Substances for Diabetic Kidney Disease Based on GraphBAN.

Current medicinal chemistry·2026
Same journal

Berberine as an Antimicrobial Agent and Gut Microbiota Modulator: Mechanisms and Therapeutic Potential.

Current medicinal chemistry·2026
Same journal

Research Progress of Grapefruit-derived Extracellular Vesicles in Anti-tumor Treatment.

Current medicinal chemistry·2026
Same journal

Corrigendum to: Neuroprotective Mechanisms of Oxygen and Ethanol: A Potential Combination Therapy in Stroke.

Current medicinal chemistry·2026
Same journal

Ferroptosis and Its Crosstalk with Other Cell Death Modes in Ischemic Stroke.

Current medicinal chemistry·2026
Same journal

Integrative Analysis Reveals BPTF, COL1A1, and COL4A2 as Fibroblast-Related Biomarkers Associated with Immune Infiltration in Ovarian Cancer.

Current medicinal chemistry·2026
See all related articles

Calcitonin (CT) is a hormone that inhibits bone resorption, making it useful for treating bone disorders like osteoporosis. Research explores its physiology, receptor interactions, and potential for new therapies.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Pharmacology

Background:

  • Calcitonin (CT) discovered in 1962 as a hypocalcemic hormone.
  • CT inhibits osteoclast-mediated bone resorption, underpinning its use in bone disorders.
  • Clinical applications include Paget's disease, osteoporosis, and hypercalcemia of malignancy.

Purpose of the Study:

  • Review the basic physiology and structure-function of calcitonin (CT) peptides.
  • Examine CT receptor cloning, isoforms, signaling, and regulation.
  • Discuss current and potential future therapeutic uses of CT and its mimetics.

Main Methods:

  • Literature review of calcitonin physiology and pharmacology.
  • Analysis of structure-function studies on CT peptides.

Related Experiment Videos

  • Examination of research on CT receptor biology, including cloning and alternative splicing.

    • Main Results:

    • CT's primary action is inhibiting bone resorption via osteoclasts.
    • Identified CT receptor isoforms arise from alternative mRNA splicing.
    • CT receptor signaling and regulation mechanisms are being elucidated.

    Conclusions:

    • Calcitonin is a key hormone for bone metabolism regulation.
    • Understanding CT-receptor interactions and signaling is crucial for therapeutic development.
    • Advances in peptide delivery and CT mimetics may expand therapeutic applications for bone diseases.